Maximov, PY, Lee, TM, Jordan, VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013; 8: 135–55.CrossRefGoogle ScholarPubMed

Burstein, HJ, Temin, S, Anderson, H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Published online before print May 27, 2014.Google Scholar

Davies, C, Pan, H, Godwin, J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805–16.CrossRefGoogle Scholar

Harvey, HA, Kimura, M, Hajba, A. Toremifene: an evaluation of its safety profile. Breast 2006; 15: 142–57.CrossRefGoogle ScholarPubMed

Vogel, VG, Costantino, JP, Wickerham, DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727–41.CrossRefGoogle ScholarPubMed

Ettinger, B, Black, DM, Mitlak, BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–45.CrossRefGoogle ScholarPubMed

Portman, DJ, Bachmann, GA, Simon, JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013; 20: 623–30.Google ScholarPubMed

Simon, JA, Lin, VH, Radovich, C, Bachmann, GA, Ospemifene study group. One-year long-term safety extension study of ospemifene for the treatment of valvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2012; 20: 418–27.Google Scholar

Lobo, RA, Pinkerton, JV, Gass, MLS, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic bone parameters and overall safety profile. Fertil Steril 2009; 92: 1025–38.CrossRefGoogle Scholar

Pinkerton, JV, Utian, WH, Constantine, GD, Olivier, S, Pickar, JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116–24.Google ScholarPubMed

Lindsay, R, Gallagher, JC, Kagan, R, Pickar, JH, Constantine, G. Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene/conjugated estrogens (BZX/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; 92: 1045–52.CrossRefGoogle Scholar

Pinkerton, JV, Harvey, JA, Lindsay, R, et al.; SMART-5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99: E189–98 [Epub Jan 17, 2014].CrossRefGoogle ScholarPubMed

Kagan, R, Williams, RS, Pan, K, Mirkin, S, Pickar, JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010; 17: 281–9.Google ScholarPubMed

Pinkerton, JV, Harvey, JA, Pan, K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013; 121: 959–68.CrossRefGoogle ScholarPubMed

Archer, DF, Lewis, V, Carr, BR, Olivier, S, Pickar, JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; 92: 1039–44.CrossRefGoogle ScholarPubMed

Pickar, JH, Yeh, I-T, Bachmann, G, Speroff, L. Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92: 1018–24.CrossRefGoogle ScholarPubMed